CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2014
Net Income	-217.14	-153.61	-650.18	377.66	-348.87	66.86	Upgrade
Depreciation & Amortization	19.62	19.84	24.17	17.95	9.18	4.73	Upgrade
Share-Based Compensation	79.56	81.03	97.95	102.39	66.02	44.06	Upgrade
Other Operating Activities	-41.46	-207.63	32.32	40.97	35.3	-58.96	Upgrade
Operating Cash Flow	-159.42	-260.38	-495.74	538.97	-238.37	56.68	Upgrade
Capital Expenditures	-7.13	-9.47	-37.19	-81.71	-18.36	-6.68	Upgrade
Acquisitions	0	0	0	0	0	8.01	Upgrade
Change in Investments	168.65	386.62	-221.47	-953.73	-522.81	0	Upgrade
Other Investing Activities	-2.5	-2.5	-	-	-	-	Upgrade
Investing Cash Flow	159.02	374.65	-258.66	-1,035.43	-541.17	1.33	Upgrade
Share Issuance / Repurchase	363.19	62.66	38.59	250.95	1,016	430.98	Upgrade
Financing Cash Flow	363.19	62.66	38.59	250.95	1,016	430.98	Upgrade
Exchange Rate Effect	0.03	0.07	-0.08	-0.01	0.04	0.02	Upgrade
Net Cash Flow	362.82	177.01	-715.88	-245.52	236.66	489	Upgrade
Free Cash Flow	-166.55	-269.85	-532.93	457.27	-256.72	49.99	Upgrade
Free Cash Flow Margin	-61.30%	-72.69%	-44484.89%	49.98%	-35705.70%	17.26%	Upgrade
Free Cash Flow Per Share	-2.04	-3.41	-6.86	6.02	-3.89	0.92	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).